Research

Why Curaderm?

#Curaderm-BEC5 is an ideal therapy for skin cancer.
#Curaderm-BEC5 is clinically proven for all types of Non-Melanoma skin cancer.
#Curaderm-BEC5 is cosmetically effective.
#Curaderm-BEC5 lowers the percentage of recurrence.
#Curaderm-BEC5 is safe to use.
Curaderm-BEC5 destroys cancer cells without affecting the normal cells. Curaderm-BEC5 treats the Cancer on the surface of the skin tissue and the deep penetrating delivery cream allows the active to penetrate the skin and attack the whole cancer.

Skin Cancer Research:

#The intenationally patented Active Ingredient “BEC” and its capacity to destroy Cancer cells.
#Formulated with carrier agents to reach cancer infected cells deep in the skin tissue.
#Ensures skin cancer destruction and healthy skin tissue regrowth.
#Clinically proven effectivenesss of BEC on Skin Cancer.
#Published medical research on Curaderm-BEC5.
Curaderm-BEC5 Published Research
Over the last few decades, medical research has been published showing evidence of Curaderm-BEC5 as a safe and effective skin cancer treatment Highly respectable journals such as; Cancer Letters, Drugs of the Future, Asia Pacifc Journal of Pharmacology, Planta Med and Drugs of Today, have published medical research on Curaderm-BEC5 from 1987 and 2003.

Such journals are read by medical practioners and scientific researchers so they can be informed of important medicinal developments. Curadern has passed every toxicology and safety data as well as documented the effectiveness of Curaderm-BEC5 to destroy cancer cells with minimal or no cosmetic scarring or unhealthy side effects.

The option to treat Skin cancer with Curaderm-BEC5 has been available since 1982. By 2003, when the Phase 3 clinical trials were released, over 80,000 patients had already used and successfully treated their skin cancers with Curaderm-BEC5. So over 80,000 people are testimonial to how well Curaderm-BEC5 works on their skin lesions.
Cham, B. E. and Wilson, L. (1987). HPLC of glycoalkaloids from Solanum sodomaeum L. Planta Med. 53, 59-61.

Bajaj, K. L., Kaur, G. and Chada, M. L. (1979). Glycoalkaloid content and other chemical constituents of the fruits of some egg plant (Solanum melongena, L.)

varieties. J. Plant Foods, 3, 163-168.

Chen, Z. and Miller, A. (2001). Steroidal Alkaloids in solanaceous vegetable crops. Horticul. Rev. 25. 171- 186.

Ghazi, M. and Matthees, D. P. (1989). Use of ion-pairing reversed-phase liquid chromathography in separation of solanidine and solasodine. J. Chem. Exol. 15. 2661-

2666.

Jones, P.G. and Fenwick, G.R. (1981). The glycoalkaloid content of some edible Solanaceous fruits and potato products. J. Sci, Food Agric. 32. 419-421.

Nada, C., Nikolic, A., Mihajlo, Z., Stankovic, A. G., Dejan, Z. and Markovic, C. D. (2005). Liquid-liquid systems for acid hydrolysis of glycoalkaloids from Solanum

tuberosum L. tuber sprouts and solanidine extraction. Med. Sci. Monit. 11(7). BR200-205.

Schreiber, K. (1968). Steroidal alkaloids: The Solanum group. In the alkaloids Vol 10, (Mansk, K., Ed.). Academic Press.

Cham, B. E. (1988). Monograph on the compound BEC. Drugs of the Future. 13, 714-716.

Daunter, B. and Cham, B. E. (1990). Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters 55, 209-220.

Cham, B. E. (1989). Curaderm (antineoplastic). Launched in Australia. Drug News and Perspectives 2, 112.

Cham, B. E. (1991). Solasodine glycosides: A new modality for cancer. In Proc. 2nd Oceania Symposium. Pp.30-36.
Editor Mark S. Walker. Bioconcepts Publishing.

Cham, B. E. (1994). Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies. Asia Pacif. J.
Pharmacol. 9, 113-118.

Cham, B. E. (1993). Efficacy and mode of action of solasodine glycosides (BEC) on cancer cells. In Proc. 4th Oceania
Symposium 0041-51. Editor Mark S. Walker. Bioconcepts Publishing.

Chataing, B., Christancho, N. B. and Usubillaga, A. (1998). Topical treatment of herpes simplex, herpes zoster and genital herpes with a mixture of Solanaceous

glycoalkaloids. MedULA. Universidad de Los Andes. 7. 30-34.

Choi, E. and Koo, S. (2005). Anti-nociceptive and anti-inflam matory effects of the ethanolic extract of potato (Solanum
tuberosum). Food Agri. Immun. 16. 29-39.

Hall, C. A., Hobby, T. and Cipollini, M. (2006). Efficacy and Mechanisms of α- Solasonine-and α-Solamargine-Induced Cytolysis on Two Strains of Trypanosoma cruzi.

J.Chem. Ecol. 32. 2405-2416.

Kuo, K. W., Hsu, S. H., Li, Y. P., Lin, W. L., Liu, L. F., Chang, L. C., Lin, C. C., Lin, C. N. and Sheu, H. M. (2000). Anti cancer activity evaluation of the Solanum

glycoalkaloid
solamargine. Triggering apoptosis in human hepatoma cells. Biochem. Pharmacol. 60, 1865-1873.

Putalun, W., Taura, F., Qing, W., Matsushita, H., Tanaka, H and Shoyama, Y. (2003). Anti-solasodine glycoside single- chain Fv antibody stimulates biosynthesis of

solasodine glycoside in plants. Plant Cell Rep. 22. 344-349.

Verpoorte, R. (1998). Exploration of nature’s chemodiversity: the role of secondary metabolites as leads in drug development. Drug Discov. Today 3, 232-238.

Vijayan, P., Vinod Kumar, S., Dhanaraj, S. A., Badami, S. and Suresh, B (2002). In Vitro Cytotoxicity and Anti-tumour Properties of the Total Alkaloid Fraction of

Unripe Fruits of Solanum pseudocapsicum. Pharmaceut. Biol. 40. 456-460.

Cham, B. E., Gilliver, M. and Wilson, L. (1987). Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum L. Planta Med. 53, 34-36.

Cham, B. E., Daunter, B. (1990). Solasodine glycosides. Selective cytoxicity for cancer cells and inhibition of
cytotoxicity by rhamnose in mice with sarcoma 180. Cancer Letters, 55, 221-225.

Amalfi, C. (2006). The little mouse who wouldn’t say die. Cosmos Mag. 471.

Badami, S., Manohara Reddy, S.A., Kumar, E.P., Vijayan, P. and Suresh, B. (2003). Antitumour activity of total alkaloid fraction of Solanum pseudocapsicum leaves.

Phytother. Res. 17. 1001-1004.

Chataing, B., Concepcion, J. L., Lobaton, R. and Usubillaga, A. (1998). Inhibition of Trypanosoma cruzi growth in vitro by Solanum alkaloids; a comparison with

ketoconazole. Planta Med. 64, 31-36.

Chami, L.A., Méndez, R., Chataing, B., O’Callaghan, J., Usubillaga, A. and LaCruz, L. (2003). Toxicological effects of α-solamargine in experimental animals. Phyto

Res. 17, 254- 258.

Chang, L. C., Tsai, T. R., Wang, J. J., Lin, C. N. and Kuo, K. W. (1998). The rhamnose moiety of solamargine plays a
crucial role in triggering cell death by apoptosis. Biochem. Biophys. Res. Commun. 242, 21-25.

Esteves-Souza, A., Silva, T. M. and Alves, C. C. F. et al. (2002). Cytotoxic activities against Ehrlich carcinoma and human K562 leukaemia of alkaloids and flavonoid

from two Solanum Species. J. Braz. Chem. Soc. 13. 838-842.

Hsu, S. H., Tsai, T. R., Lin, C. N., Yen, M. H. and Kuo, K. W. (1996). Solamargine purified from Solanum incanum
Chinese herb triggers gene expression of human TNFR1 which may lead to cell apoptosis. Biochem. Biophys. Res. Commun. 229, 1-5.

Evans, R., Cham, B. E. and Daunter, B. (1989). Letter to the Editor. Your Pharmacy, January, 1.

Cham, B. E. and Meares, M. M. (1987). Glycoalkaloids from Solanum sodomaeum L. are effective in the treatment of skin cancers in man. Cancer Letters 36, 111-118.

Cham, B. E., Daunter, B and Evans, R. (1992). Topical
treatment of malignant and premalignant skin cancers by very low concentration of a standard mixture of solasodine glycosides. Clinical Digest Series. Dermatology.

1992.

Cham, B. E., Daunter, B and Evans, R. (1991). Topical
treatment of malignant and premalignant skin cancers by very low concentrations of a standard mixture of solasodine glycosides. Cancer Letters 59, 183-192.

Cham, B. E., Daunter, B and Evans, R. (1990). Curaderm. Med. J. Australia. 152, 329-330.

Cham, B. E., Daunter, B. (1990). Topical treatment of
pre-malignant and malignant skin cancers with Curaderm. Drugs of Today 26, 55-58.

Cham, B. E. (1989). Plants yield skin cancer cure. Austral. Technol. Rev. 2, 53.

Millward, M., Powell, A., Daly, P., Tyson, S., Ferguson, R.
and Carter, S. (2006). Results of phase I clinical trials of
Coramsine in patients with advanced solid tumours.
J. Clin. Oncol. 24, 2070.

Nakamura, T., Komori, C., Lee, Y., Hashinoto, F., Yahara, S., Nohara, T., and Ejina, A. (1996). Cytotoxic activities of
Solanum steroidal glycosides. Biol. Biopharm. Bull. 19, 564- 566.

Roddick, J. G., Rÿrenber, A. L. and Weissenber, M. (1990). Membrane-disrupting properties of the steroidal glycoalkaloids Solasonine and Solamargine. Phyto. Chem. 29.

1513-1518.

Roddick, J. G., Weissenberg, M. and Leonard, A. L. (2001). Membrane disruption and enzyme inhibition by naturally – occurring and modified chaco-triose – containing

Solanum steroidal glycoalkaloids. Phyto. Chem. 56, 603-610.

Jellinek, N. and Maloney, M. (2005). Escharotic and other botanical agents for the treatment of skin cancer: A review. J. Amer. Aca. Dermatol. 53. 486-495.

Moss, R. W. (1998). Herbs against cancer History and
controversy. Equinax press, Inc. Brooklyn, N.Y.

Punjabi, S., Cook, I., Kersey, P., Marks, R., Finlay, A., Sharpe, G. et al. (2000). A double blind, multi-centre parallel group study of BEC-5 cream in basal cell

carcinoma. Eur. Acad.
Dermatol. Venereol. 14 (Suppl). 47-60.

Walsh, N. (2000). Promising Topical Therapy for Actinic
Keratoses – Brief Article Dr S Punjabi. Uni. Liverpool.
Family Pratice News. December 1 article.

Williams, D. G. (1995). The skin cancer cure nobody wants you to know about. Alternatives, 6, 17-22. Mountain Home Publishing.

Williams, D. G. (1995). The skin cancer cure so effective, it’s being kept secret. Ingram, TX: Mountain Home Publishing.

Sussman, L.A.E. and Liggins, D.F. (1996). Incompletely
excised basal cell carcinoma: a management dilemma? Aust. NZ. J. Surg. 66, 276-278.

Cham, B.E. (2007). Solasodine rhamnosyl glycosides in a cream formulation is effective for treating large and trouble some skin cancers. Res. J. Biol. Sci. 2(7) 749-

761.

Caramelli, B., dos Santos Filho, R. D., Sposito Ade, C. and Martinez, T. L. (1998). Effect of eggplant on plasma lipid
levels, lipidic peroxidation and the reversion of endothelial dysfunction in experimental hypercholesterolemia. Arq. Bras. Cardiol. 71(1). 89.

Guimaraes, P. R., Galvao, A.M., Batista, C. M., Azevedo, G. S., Oliveira, R. D., Lamounier, R. P., Freire, N., Barros, A. M., Sakurai, E., Oliveira, J. P., Vieira, E.

C. and Alvarez- Leite, J. I. (2000). Eggplant (Solanum melongena) infusion has a modest and transitory effect on hypercholesterolemic subjects. Braz. J. Med. Biol.

Res. 33(9). 1027-1036.

Marchiori Praça, J., Thomaz, A. and Caramelli, B. (2004). Eggplant (Solanum melongena) extract does not alter serum lipid levels. Arq. Bras. Cardiol. 82.(3). 269-272.

Ono, M., Nishimura, K., Suzuki, K., Fukushima, T., Igoshi, K., Yoshimitsu, H., Ikeda, T. and Nohara, T. (2006). Steroidal glycosides from the underground parts of

Solanum
sodomaeum. Chem. Pharm. Bull. 54, 230-233.

Cham, B.E. (2007). Solasodine rhamnosyl glycosides
specifically bind cancer cell receptors and induce apoptosis and necrosis. Treatment for skin cancer and hope for internal
cancers. Res. J. Biol. Sci. 2(4) 503-514.

What are other Options to Treat Skin Cancer?
There are various forms of treatment conventially used by medical experts to treat skin cancer. Including:

#Surgery
#Radiotherapy
#Dermatological
Limitations of Conventional Skin Cancer Treatments
If you are reading through this information you or someone close to you has probably been diagnosed with a type of skin cancer and interested to know the options you have available to you. The following limitations apply to all commonly used skin cancer treatments:

#Formation of scar tissue
#Lack of normal tissue regrowth i.e loss of skin tissue.
#Limited access to cancer within the lesion in deep skin tissue.
#A high rate of recurrence of the skin cancer